ARID1B

Across TCGA pan-cancer cohorts, ARID1B Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ARID1B data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ARID1B Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARID1B expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

CESC, BLCA, and SKCM are the cancer types where ARID1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.244	0.737	.012	12	view →
BLCA	DFS	Median	All	1.000	0.297	.013	12	view →
SKCM	OS	Median	All	0.683	0.877	<.001	10	view →
LIHC	DFS	Median	III,IV	0.118	0.366	.013	9	view →
UCEC	DFS	Median	II,III,IV	0.879	0.433	.029	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
COAD	DFS	Median	All	1.000	0.669	.025	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ESCA	OS	Median	II,III,IV	0.397	0.715	.009	3	view →
THCA	DFS	Median	All	0.196	0.830	.027	2	view →
LUSC	DFS	Median	II,III,IV	0.317	0.602	.014	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ARID1B–CESC (DFS)

Open the CESC breakdown →